Learn about diagnosing close contact with QuantiFERON-TB Gold Plus positive results. This resource provides information on clinical documentation, medical coding, and healthcare guidelines for managing latent tuberculosis infection (LTBI) following exposure to a person with active TB. Understand the implications of a positive IGRA test in contacts and best practices for TB prevention and treatment. Explore accurate diagnostic criteria and appropriate medical terminology for TB exposure and LTBI.
Also known as
Contact with and exposure to tuberculosis
Contact with a person with positive QuantiFERON test.
Latent tuberculosis infection
Latent tuberculosis, not currently active.
Contact with and exposure to tuberculosis
Contact with and exposure to pulmonary tuberculosis.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is there documented evidence of active TB disease?
When to use each related code
| Description |
|---|
| TB exposure with positive blood test (IGRA). |
| TB exposure, infection unclear. |
| Active tuberculosis infection. |
Coding lacks specificity regarding the type of contact (household, occupational, etc.), impacting risk assessment and public health reporting accuracy. Keywords: ICD-10 Z20.828, Contact tracing, Exposure coding
Misdiagnosis of latent TB infection (LTBI) as active TB can lead to inappropriate treatment and overreporting. Keywords: Latent tuberculosis, IGRA interpretation, A15 vs. Z20.828
Insufficient documentation of quantiferon results and contact details hinders accurate coding and compliance audits. Keywords: CDI query, Clinical validation, TB diagnosis documentation
Q: How should I manage a patient with a positive QuantiFERON-TB Gold test after close contact with active pulmonary tuberculosis?
A: Managing a patient with a positive QuantiFERON-TB Gold (QFT-GIT) test after close contact with active pulmonary tuberculosis requires a multi-pronged approach. First, rule out active TB disease through clinical evaluation, including symptom assessment (e.g., cough, fever, weight loss), chest X-ray, and potentially sputum analysis. If active TB is excluded, the patient is considered to have latent tuberculosis infection (LTBI). Treatment for LTBI is crucial to prevent progression to active disease. Several treatment regimens are available, such as isoniazid for 6 or 9 months, rifampin for 4 months, or isoniazid and rifapentine weekly for 3 months. The choice of regimen depends on patient factors like potential drug interactions and adherence concerns. Consider implementing a patient education program to ensure adherence to the chosen regimen. Explore how different LTBI treatment regimens impact patient outcomes and adherence rates to make informed decisions. It's also crucial to conduct contact tracing to identify and evaluate other individuals potentially exposed to the index case. Learn more about the updated CDC guidelines for TB diagnosis and treatment.
Q: What are the key considerations in differentiating between latent TB infection (LTBI) and active tuberculosis disease after a known TB exposure with a positive IGRA?
A: Differentiating between latent TB infection (LTBI) and active tuberculosis disease after a known TB exposure and a positive interferon-gamma release assay (IGRA), like the QuantiFERON-TB Gold test, relies on a combination of factors. While a positive IGRA indicates TB infection, it doesn't distinguish between LTBI and active disease. Clinicians should carefully evaluate patients for symptoms suggestive of active TB, such as persistent cough, fever, night sweats, weight loss, and hemoptysis. A chest X-ray is essential to look for abnormalities consistent with active TB, such as infiltrates, cavitations, or pleural effusions. Sputum smear and culture are also important for confirming active pulmonary TB. In patients with a positive IGRA but no clinical or radiographic evidence of active TB, the diagnosis is LTBI. Consider implementing a standardized protocol for evaluating individuals with suspected TB exposure to ensure consistent and comprehensive assessment. Explore how advancements in diagnostic techniques can further improve the accuracy of differentiating between LTBI and active TB.
Patient presents for evaluation of latent tuberculosis infection (LTBI) due to close contact with a QuantiFERON-TB Gold Plus test-positive individual. The patient reports no symptoms suggestive of active tuberculosis, such as fever, night sweats, cough, or weight loss. Physical examination reveals no abnormalities. The patient's exposure history includes recent close contact with a confirmed case of active pulmonary tuberculosis, subsequently diagnosed with a positive QuantiFERON-TB Gold Plus test. Given the significant exposure and potential for latent TB infection, further evaluation is warranted. Differential diagnoses include latent TB infection, no TB infection, and active pulmonary tuberculosis. A tuberculin skin test (TST) or QuantiFERON-TB Gold Plus test will be ordered to assess for LTBI. Patient education regarding tuberculosis transmission, prevention, and the importance of adherence to treatment if LTBI is diagnosed was provided. Follow-up appointment scheduled to discuss test results and potential treatment options, including isoniazid preventive therapy if indicated. ICD-10 code Z20.822 (contact with and exposure to tuberculosis) and CPT code 86580 (QuantiFERON-TB Gold Plus) are relevant for this encounter. The patient understands the plan of care and agrees to return for follow-up.